Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.

European journal of cancer (Oxford, England : 1990) - 1 Jan 2024

Wagner Nikolaus B, Lenders Max M, Kühl Kathrin, Reinhardt Lydia, Fuchß Milena, Ring Natalie, Stäger Ramon, Zellweger Caroline, Ebel Chiara, Kimeswenger Susanne, Oellinger Angela, Amaral Teresa, Forschner Andrea, Leiter Ulrike, Klumpp Bernhard, Hoetzenecker Wolfram, Terheyden Patrick, Mangana Joanna, Loquai Carmen, Cozzio Antonio, Garbe Claus, Meier Friedegund, Eigentler Thomas K, Flatz Lukas

Abstract excerpt

BACKGROUND: Targeted therapy (TT) of BRAF V600 mutated unresectable melanoma with inhibitors of the MAPK pathway achieves response rates of up to 76%, but most patients develop secondary resistance. Albeit TT is strikingly efficacious during the first days of treatment, even in advanced cases, long-term survival is highly unlikely, especially in patients with unfavorable baseline characteristics like elevated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRAF gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Mutation

Share to Prognosis

Share to Progression-Free Survival

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Source

Identifiers

PMID: 38039778
DOI: 10.1016/j.ejca.2023.113425

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.PMID 38039778Read ↗

Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.Semantic proximity Read ↗

Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy.Semantic proximity Read ↗

Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.Semantic proximity Read ↗

Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib.Semantic proximity Read ↗

Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.Semantic proximity Read ↗

Prognostic Clinical and Radiographic Biomarkers for BRAF-Targeted Therapy in Advanced Melanoma.Semantic proximity Read ↗

Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.Semantic proximity Read ↗

TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.Semantic proximity Read ↗

Development of a Nomogram to Predict Therapeutic Resistance in Metastatic Melanoma Using Longitudinal ctDNA Kinetics.Semantic proximity Read ↗

Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.Semantic proximity Read ↗

Evaluation of Prognostic Markers for Progression-Free Survival of Metastatic Melanoma Patients Treated with First-Line Ipilimumab Plus NivolumabSemantic proximity Read ↗

Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarkerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.